Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Sinopharm

- PMLiVE

WHO report shows progress as well as gaps in AMR antibiotic pipeline

AMR has been declared as one of the top ten global public health threats by the organisation

- PMLiVE

Novavax announces positive phase 2 results for COVID-19/influenza vaccine candidates

A combination COVID-19/influenza vaccine is included in the mid-stage study

- PMLiVE

WHO declares end to COVID-19 global public health emergency

The agency’s emergency committee said it is time to transition to long-term management of the pandemic

- PMLiVE

WHO announces launch of new pandemic preparedness initiative

The guidance focuses on respiratory pathogens, including influenza and RSV

- PMLiVE

WHO and global partners launch new effort to address falling childhood vaccination rates

Over 25 million children missed at least one vaccination in 2021 alone

- PMLiVE

WHO releases largest global collection of publicly available health inequality data

The repository is composed of nearly 11 million data points across more than 2,000 indicators

- PMLiVE

NHS spring COVID-19 booster programme opens up for those at highest risk

Around five million people are eligible for the booster in line with the JCVI’s advice

- PMLiVE

Authorisation for Moderna and Pfizer/BioNTech’s bivalent COVID-19 vaccines simplified by FDA

The vaccines are now authorised for all doses in individuals aged six months and older

- PMLiVE

Gilead’s COVID-19 treatment shows promising results in vulnerable patient populations

Veklury demonstrated a reduction in mortality and hospital readmission rates

- PMLiVE

BioNTech reveals plans to spend about €1bn more on research and development this year

The company has already started clinical trials assessing four new infectious disease vaccines

- PMLiVE

WHO report highlights impact of COVID-19 pandemic on non-communicable diseases

These diseases were responsible for an estimated 40 million of all deaths globally in 2019

- PMLiVE

Pfizer/BioNTech’s Omicron-adapted booster approved by FDA for young children

The companies have also submitted an application to the EMA for this age group

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links